10-Q: Oramed Pharmaceuticals Reports Strong Q3 2026 Driven by Investment Gains

Oramed Pharmaceuticals Inc. (ORMP) reported a substantial increase in net income for the nine months ended September 30, 2026, primarily driven by significant unrealized gains from its investment portfolio, particularly in Alpha Tau.

Summary

• Oramed Pharmaceuticals Inc. reported a net income of $134.9 million for the nine months ended September 30, 2026, a significant increase from $54.0 million in the same period of 2025.
• This surge in net income was largely due to substantial unrealized gains from investments, especially in Alpha Tau, amounting to $174.5 million for the nine months ended September 30, 2026.
• Operating expenses increased, with general and administrative expenses rising by 77% to $8.9 million for the nine months ended September 30, 2026, primarily due to higher stock-based compensation.
• Research and development expenses decreased significantly by 64% to $1.6 million, attributed to the transfer of the POD technology platform to OraTech.
• The company's cash and cash equivalents decreased to $28.9 million as of September 30, 2026, from $45.9 million at the end of 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to significant unrealized gains from investments, particularly in Alpha Tau, which substantially boosted net income. While operational expenses increased, the overall financial position appears strengthened by investment performance.

Positives

• Significant unrealized gains from investments, particularly in Alpha Tau, led to a substantial increase in net income to $134.9 million for the nine months ended September 30, 2026.
• The fair value of the investment in Alpha Tau ordinary shares and warrants was approximately $252.4 million as of September 30, 2026.
• The company's cash position remains robust at $28.9 million as of September 30, 2026, providing sufficient liquidity for at least the next 12 months.
• The Lifeward transaction, which closed on March 25, 2026, resulted in Oramed receiving 1,250,363 Lifeward ordinary shares, pre-funded warrants, and share purchase warrants, along with a $9 million senior secured convertible note.
• The company's investment in Alpha Tau grants it significant influence and the right to nominate two directors to Alpha Tau's board.

Negatives

• Operating loss increased to $10.5 million for the nine months ended September 30, 2026, from $9.4 million in the prior year period, driven by higher general and administrative expenses.
• The company faces potential risks related to its investment in Scilex, with outstanding principal balances on notes and accrued interest, and a high discount rate reflecting significant credit risk.
• The company's NIS-denominated loan to Hapisga and other NIS-denominated assets expose it to foreign currency exchange rate fluctuations and concentration risk.
• General and administrative expenses increased by 77% for the nine months ended September 30, 2026, largely due to a $3.18 million increase in non-cash stock-based compensation expenses.
• The company has a significant unfunded capital commitment of approximately $1.78 million to Ruby Sapphire II.

Risks

• A substantial majority of Oramed's assets consist of its investment in Alpha Tau, and a decline in Alpha Tau's share price could materially adversely affect Oramed's financial condition and results of operations.
• Scilex has not paid its obligations under the Tranche A Note and the Tranche B Note when originally due, and Oramed may be unable to recover the amounts owed or realize the value of its collateral.
• The company's NIS-denominated loan to Hapisga and other NIS-denominated assets and commitments expose it to foreign currency exchange rate fluctuations and concentration risk.
• The company may be deemed to be an investment company under the Investment Company Act of 1940, which could require registration or significant business changes.
• The company's investment in Ruby Capital Investment Fund Sapphire II, Limited Partnership involves risks including illiquidity, capital call obligations, and potential loss of invested capital.

Future Outlook

The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund its current planned activities and expenditures for at least the next 12 months. Oramed is evaluating a range of strategic alternatives, including expanding into additional therapeutic and technology areas, and acquiring or investing in additional businesses or assets.

Management Comments

• Oramed has transformed into a strategic healthcare operating company focused on building long-term value through active ownership and operational leadership.
• We selectively acquire meaningful strategic positions in companies where we can leverage our expertise across corporate strategy, clinical and regulatory development, commercialization, capital markets, and business growth.
• By partnering closely with management and providing hands-on operational guidance, we seek to accelerate innovation and unlock the full potential of our portfolio companies.
• Our value creation is driven by operating and growing these businesses, with a focus on long-term strategic development and real-world impact.

Industry Context

StockSavvy.ai notes that Oramed's shift towards a strategic healthcare operating company model, focusing on investments and active ownership, aligns with a broader trend in the pharmaceutical and biotech sectors where companies are diversifying their strategies beyond direct R&D to leverage existing expertise and capital across a portfolio of ventures.

Comparison to Industry Standards

• The company's net income of $134.9 million for the nine months ended September 30, 2026, is significantly influenced by investment gains, which is a common strategy for companies seeking to monetize R&D assets or diversify revenue streams.
• The substantial unrealized gains from investments, particularly in Alpha Tau, highlight the importance of strategic partnerships and minority stakes in emerging biotech companies as a value driver, a practice seen across the industry.
• The decrease in R&D expenses due to the transfer of the POD technology platform to OraTech is a strategic move to reduce direct operational costs while retaining exposure to potential future upside, a common approach for companies undergoing portfolio optimization.
• The company's cash position and forward-looking statements regarding liquidity for the next 12 months are standard disclosures for companies in this sector, emphasizing prudent financial management.

Management Changes

Legal Proceedings

• Oramed is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceedings that would have an adverse effect on its business, operating results, or financial condition.

Related Party Transactions

• Consulting agreement with KNRY Ltd. (owned by Chief Scientific Officer) for services and reimbursement of expenses.
• Employment agreement with Chief Scientific Officer for salary, car benefit, and other perquisites.
• Consulting agreement with Shnida Ltd. (owned by President and CEO) for services and reimbursement of expenses.
• Employment agreement with President and CEO for salary and other perquisites.
• Investment in Alpha Tau, which is considered a related party due to significant influence and board nomination rights.
• Investment in Lifeward, which is considered a related party due to significant influence.
• Clinical Trial Management Agreement with OraTech (a subsidiary of Lifeward) for services related to the oral insulin capsule product study.

Stakeholder Impact

• Shareholders benefit from the significant increase in net income driven by investment gains, although a portion of this is unrealized.
• Employees are impacted by changes in executive compensation and the restructuring of roles, such as Joshua Hexter's reduced position.
• Creditors and noteholders (e.g., related to Scilex notes) face risks due to potential non-payment and the need for extensions.
• The company's strategic shift may impact future employment opportunities and the overall direction of the business.

Next Steps

• Oramed is evaluating a range of strategic alternatives, including expanding into additional therapeutic and technology areas, and acquiring or investing in additional businesses or assets.
• The company expects to seek additional financing through private placements and public offerings in the future, as needed.
• The company will continue to manage its portfolio of holdings in publicly traded and privately held companies.
• The company will continue to monitor its investments, including those in Lifeward, Scilex, and Alpha Tau.

Key Dates

Recommendation

While the company reported a significant increase in net income due to investment gains, the operational losses and the inherent risks associated with its investment portfolio (particularly Scilex and Alpha Tau) warrant a cautious approach. The company's future outlook depends heavily on the performance of these investments and its ability to execute its strategic alternatives. Therefore, a 'hold' recommendation is appropriate, pending further clarity on operational performance and investment outcomes.

Keywords

Oramed Pharmaceuticals, Form 10-Q, Quarterly Report, Financial Statements, Investment Portfolio, Alpha Tau, Lifeward, Scilex